Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: a real-world study and systematic review.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: a real-world study and systematic review.
- Published In:
- Cardiovascular diabetology, 20(1), 21 (2021)
- Authors:
- Yang, Chen-Yi, Chen, Ying-Ren, Ou, Huang-Tz, Kuo, Shihchen
- Database ID:
- RPEP-05899
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-05899APA
Yang, Chen-Yi; Chen, Ying-Ren; Ou, Huang-Tz; Kuo, Shihchen. (2021). Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: a real-world study and systematic review.. Cardiovascular diabetology, 20(1), 21. https://doi.org/10.1186/s12933-020-01211-4
MLA
Yang, Chen-Yi, et al. "Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: a real-world study and systematic review.." Cardiovascular diabetology, 2021. https://doi.org/10.1186/s12933-020-01211-4
RethinkPeptides
RethinkPeptides Research Database. "Cost-effectiveness of GLP-1 receptor agonists versus insulin..." RPEP-05899. Retrieved from https://rethinkpeptides.com/research/yang-2021-costeffectiveness-of-glp1-receptor
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.